Automate Your Wheel Strategy on CTMX
With Tiblio's Option Bot, you can configure your own wheel strategy including CTMX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CTMX
- Rev/Share 1.6937
- Book/Share 0.2875
- PB 7.3908
- Debt/Equity 0.3253
- CurrentRatio 1.7256
- ROIC 0.6672
- MktCap 334781000.0
- FreeCF/Share -0.936
- PFCF -4.1056
- PE 4.45
- Debt/Assets 0.0827
- DivYield 0
- ROE -5.5312
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CTMX | H.C. Wainwright | Neutral | Buy | -- | $5 | May 15, 2025 |
| Resumed | CTMX | Piper Sandler | -- | Overweight | $3.25 | $2.5 | April 14, 2025 |
News
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma.
Read More
CytomX Therapeutics: Doubling Overnight On Phase 1 Data
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Positive
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.
Read More
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by.
Read More
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.
Read More
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing …
Read More
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion ( 7.2, 8.6 and 10 mg/kg Q3W) -
Read More
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -
Read More
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
Read More
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets.
Read More
About CytomX Therapeutics, Inc. (CTMX)
- IPO Date 2015-10-08
- Website https://www.cytomx.com
- Industry Biotechnology
- CEO Dr. Sean A. McCarthy DPHIL
- Employees 119